Apimeds Pharmaceuticals US, Inc (APUS) insider trading

Every open-market stock purchase and sale by Apimeds Pharmaceuticals US, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • No open-market insider trades in the last 12 months.
  • Last insider buy: Christopher Kim (C-suite exec), $14.4K, 17 months ago.

Last 12 months: insiders bought $0 (0 buys) and sold $0 (0 sales).

Recent APUS insider trades

DateInsiderTradeValue
Nov 11, 2025Carol A O'Donnell (Director)Bought (not open market)—
Nov 11, 2025Elona Kogan (Director)Bought (not open market)—
Nov 11, 2025Jakap Koo (Director)Bought (not open market)—
Nov 11, 2025Bennett Weintraub (Director)Bought (not open market)—
Nov 11, 2025Hankil Yoon (Director)Bought (not open market)—
Oct 15, 2025Jakap Koo (Director)Bought (not open market)—
Oct 15, 2025Christopher Kim (C-suite exec)Bought (not open market)—
Oct 15, 2025Carol A O'Donnell (Director)Bought (not open market)—
Oct 15, 2025Erik C. Emerson (CEO)Bought (not open market)—
Oct 15, 2025Hankil Yoon (Director)Bought (not open market)—
Oct 15, 2025Elona Kogan (Director)Bought (not open market)—
Oct 15, 2025Bennett Weintraub (Director)Bought (not open market)—

Who's trading APUS

Get free alerts when an insider at Apimeds Pharmaceuticals US, Inc files a new trade →